Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Lymphoid leukemia

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44341   clinical trials with a EudraCT protocol, of which   7370   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    380 result(s) found for: Lymphoid leukemia. Displaying page 5 of 19.
    « Previous 1  2  3  4  5  6  7  8  9  Next» Last»»
    EudraCT Number: 2008-000434-47 Sponsor Protocol Number: IM-T-hA20-08 Start Date*: 2008-07-22
    Sponsor Name:Immunomedics, Inc.
    Full Title: A Phase I/II Study of Immunotherapy with Subcutaneous Administered Veltuzumab (hA20) in Patients with CD20+ Non-Hodgkin's Lymphoma or Chronic Lyphocytic Leukemia
    Medical condition: Non-Hodgkin's Lymphoma and Chronic Lymphocytic Leukemia
    Disease: Version SOC Term Classification Code Term Level
    9.1 10029547 Non-Hodgkin's lymphoma LLT
    9.1 10008976 Chronic lymphocytic leukemia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2005-005719-83 Sponsor Protocol Number: ATGfamilystudy Start Date*: 2007-01-30
    Sponsor Name:University Hospital Hamburg-Eppendorf
    Full Title: Prophylaxis of chronic graft-versus-host disease (cGvHD) with or without anti-T-lymphocyte-globulin (ATG Fresenius) prior allogeneic peripheral stem cell transplantation from HLA-identical siblings...
    Medical condition: acute lymphoblastic and myeloid leukemia
    Disease: Version SOC Term Classification Code Term Level
    8.1 10024330 Leukemia acute LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed) IT (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2013-005343-82 Sponsor Protocol Number: GS-US-312-1325 Start Date*: 2014-05-15
    Sponsor Name:Gilead Sciences, Inc.
    Full Title: An Expanded Access Protocol for Idelalisib in Combination with Rituximab for Relapsed, Previously Treated Subjects with Chronic Lymphocytic Leukemia
    Medical condition: Chronic lymphocytic leukemia
    Disease: Version SOC Term Classification Code Term Level
    16.1 100000004864 10068919 B-cell chronic lymphocytic leukemia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed) IE (Completed) GB (Completed)
    Trial results: View results
    EudraCT Number: 2011-005174-27 Sponsor Protocol Number: HYDRIC Start Date*: 2012-06-04
    Sponsor Name:Cliniques universitaires Saint Luc
    Full Title: Phase II study of High-Dose Rituximab in High Risk Chronic Lymphocytic Leukemia in Suboptimal Response after Induction Immunochemotherapy
    Medical condition: Patients with B-cell CLL who (1) fail to achieve eradication of minimal residual disease (MRD) after standard treatment (immunochemotherapy) of their disease, (2) who have recurrence of MRD at any ...
    Disease: Version SOC Term Classification Code Term Level
    17.1 100000004864 10068919 B-cell chronic lymphocytic leukemia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed)
    Trial results: View results
    EudraCT Number: 2021-000311-23 Sponsor Protocol Number: PS-CLL-008 Start Date*: 2021-06-04
    Sponsor Name:OSPEDALE SAN RAFFAELE
    Full Title: Fixed-duration therapy with ibrutinib and obinutuzumab (GA-101) in treatment-naïve patients with CLL
    Medical condition: chronic lymphocytic leukemia/small lymphocytic lymphoma
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004864 10008976 Chronic lymphocytic leukemia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2020-001663-90 Sponsor Protocol Number: RP6530-1803 Start Date*: 2020-08-10
    Sponsor Name:Rhizen Pharmaceuticals SA
    Full Title: An Open label, Compassionate Use Study of Tenalisib (RP6530) in Patients currently receiving treatment on Tenalisib trials in Hematological Malignancies
    Medical condition: Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL)
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004864 10008976 Chronic lymphocytic leukemia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: PL (Prematurely Ended) BG (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2006-006152-34 Sponsor Protocol Number: EFC6663 Start Date*: 2007-11-28
    Sponsor Name:Sanofi-aventis recherche & développement
    Full Title: A Multicenter, Open-Label, Single Arm Study of Weekly Alvocidib in Patients with Previously Treated B-Cell Chronic Lymphocytic Leukemia (CLL) or Prolymphocytic Leukemia (PLL) Arising from CLL
    Medical condition: B-Cell Chronic Lymphocytic Leukemia (CLL) or Prolymphocytic Leukemia (PLL) arising from CLL
    Disease: Version SOC Term Classification Code Term Level
    8.1 10009310 CLL LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) IT (Completed) NL (Completed) FR (Completed) BE (Completed) DE (Completed)
    Trial results: View results
    EudraCT Number: 2022-000380-46 Sponsor Protocol Number: 75276617ALE1003 Start Date*: 2022-12-27
    Sponsor Name:Janssen-Cilag International NV
    Full Title: A Phase I/Ib Study of JNJ-75276617 in Combination with Conventional Chemotherapy for Pediatric and Young Adult Participants with Relapsed/Refractory Acute Leukemias Harboring KMT2A, NPM1, or Nucleo...
    Medical condition: Relapsed/Refractory Acute Leukemias Harboring KMT2A, NPM1, or Nucleoporin Gene Alterations
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004864 10000844 Acute lymphoblastic leukaemia LLT
    21.0 100000004864 10060354 Acute myeloblastic leukaemia LLT
    21.0 100000004864 10000833 Acute leukaemia of unspecified cell type LLT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2011-002566-21 Sponsor Protocol Number: CD-ON-MEDI-551-1019 Start Date*: 2012-07-18
    Sponsor Name:MedImmune, LLC
    Full Title: A Phase 2 Open-label Study of MEDI-551 and Bendamustine vs Rituximab and Bendamustine in Adults With Relapsed or Refractory CLL
    Medical condition: Relapsed or refractory chronic lymphocytic leukemia (CLL)
    Disease: Version SOC Term Classification Code Term Level
    16.0 100000004864 10008976 Chronic lymphocytic leukemia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) BE (Completed) IT (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2012-002795-13 Sponsor Protocol Number: RG_12-129 Start Date*: 2012-12-12
    Sponsor Name:University of Birmingham
    Full Title: A phase II trial of Cyclosporin A in Early Adverse Risk CLL
    Medical condition: Chronic Lymphocytic Leukaemia
    Disease: Version SOC Term Classification Code Term Level
    17.0 100000004864 10068919 B-cell chronic lymphocytic leukemia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2011-004672-11 Sponsor Protocol Number: SNOXA12C201 Start Date*: 2012-03-05
    Sponsor Name:NOXXON Pharma AG
    Full Title: A multi-centre, open label, uncontrolled, Phase IIa clinical trial evaluating the safety and efficiacy of NOX-A12 in combination with a background therapy of bendamustine and rituximab (BR) in prev...
    Medical condition: Relapsed chronic lymphocytic leukemia
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10008958 Chronic lymphocytic leukaemia PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) BE (Completed) IT (Completed) AT (Completed)
    Trial results: View results
    EudraCT Number: 2011-005329-27 Sponsor Protocol Number: LLC0911 Start Date*: 2013-07-30
    Sponsor Name:G.I.M.EM.A.Gruppo Italiano Malattie Ematologiche dell'Adulto
    Full Title: Phase 2 multicenter study to assess the efficacy and the safety of front-line Fludarabine, Cyclophosphamide and Ofatumumab (FCO2) chemoimmunotherapy in young (≤65 yrs) patients with Chronic Lymp...
    Medical condition: Chronic Lymphocytic Leukemia
    Disease: Version SOC Term Classification Code Term Level
    14.1 100000004864 10008976 Chronic lymphocytic leukemia LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2005-005074-69 Sponsor Protocol Number: CAM203 Start Date*: 2006-07-05
    Sponsor Name:Genzyme Europe BV
    Full Title: Phase II Trial to Evaluate the Efficacy and Safety of Subcutaneously Administered Alemtuzumab (CAMPATH, MabCampath) in Patients with Previously Treated B Cell Chronic Lymphocytic Leukemia
    Medical condition: B-Cell Chronic Lymphocytic Leukemia
    Disease: Version SOC Term Classification Code Term Level
    8.1 10008976 Chronic lymphocytic leukemia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) BE (Completed) CZ (Completed)
    Trial results: View results
    EudraCT Number: 2009-012152-24 Sponsor Protocol Number: ABT4710n Start Date*: 2011-10-24
    Sponsor Name:Abbott GmbH & Co. KG
    Full Title: A PHASE II, MULTICENTER, RANDOMIZED, CONTROLLED, OPEN-LABEL STUDY OF THE SAFETY, EFFICACY AND PHARMACOKINETICS OF ABT-263 IN COMBINATION WITH DOSE-INTENSIVE RITUXIMAB, OR DOSE-INTENSIVE RITUXIMAB A...
    Medical condition: B Cell Chronic Lymphocytic Leukemia
    Disease: Version SOC Term Classification Code Term Level
    14.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10008956 Chronic lymphatic leukaemia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Prematurely Ended) GB (Prematurely Ended) IT (Prematurely Ended) PL (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2009-013651-29 Sponsor Protocol Number: AGMT_CLL8/A Start Date*: 2010-01-13
    Sponsor Name:AGMT
    Full Title: MABTENANCE: International, Multicentre, Randomized Phase III Study of Rituximab as Maintenance Treatment versus Observation alone in Patients with Chronic Lymphocytic Leukemia
    Medical condition: Chronic Lymphocytic Leukemia
    Disease: Version SOC Term Classification Code Term Level
    19.0 100000004864 10009310 CLL LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Completed) SK (Completed) CZ (Completed) BG (Completed)
    Trial results: View results
    EudraCT Number: 2012-003101-10 Sponsor Protocol Number: CD-ON-CAT-8015-1036 Start Date*: 2013-05-03
    Sponsor Name:MedImmune, LLC
    Full Title: A Phase 2, Multicenter, Single-arm Study of Moxetumomab Pasudotox in Pediatric Subjects with Relapsed or Refractory Pediatric Acute Lymphoblastic Leukemia (pALL) or Lymphoblastic Lymphoma of B-cel...
    Medical condition: Rediatric Subjects with Relapsed or Refractory Pediatric Acute Lymphoblastic Leukemia (pALL) or Lymphoblastic Lymphoma of B-cell Origin
    Disease: Version SOC Term Classification Code Term Level
    17.0 100000004864 10000845 Acute lymphoblastic leukemia LLT
    17.0 100000004864 10003939 B-lymphoblastic lymphoma (Kiel Classification) LLT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: GB (Completed) DE (Completed) FR (Completed) IT (Completed) ES (Completed) NL (Completed)
    Trial results: View results
    EudraCT Number: 2019-000270-29 Sponsor Protocol Number: PreVent-ACaLL Start Date*: 2019-10-09
    Sponsor Name:Rigshopitalet/Copenhagen University Hospital
    Full Title: Short-term combined acalabrutinib and venetoclax treatment of newly diagnosed patients with CLL at high risk of infection and/or early treatment, who do not fulfil IWCLL treatment criteria for trea...
    Medical condition: Chronic Lymphocytic Leukemia
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004864 10009310 CLL LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Trial now transitioned) SE (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2015-005317-68 Sponsor Protocol Number: ACE-CL-208 Start Date*: 2016-05-16
    Sponsor Name:Acerta Pharma B.V.
    Full Title: A Phase 2 Study of the Efficacy and Safety of ACP-196 in Subjects with Relapsed/Refractory CLL and Intolerant of Ibrutinib Therapy
    Medical condition: High Risk Chronic Lymphocytic Leukemia
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004864 10008976 Chronic lymphocytic leukemia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) BE (Completed) ES (Completed) FR (Completed)
    Trial results: (No results available)
    EudraCT Number: 2019-004337-17 Sponsor Protocol Number: HO159 Start Date*: 2020-07-23
    Sponsor Name:HOVON Foundation
    Full Title: REtreatment with VEnetoclax and Acalabrutinib after venetoclax Limited duration (REVEAL) A prospective, multicenter, phase-II trial of venetoclax plus acalabrutinib in patients who have relapsed a...
    Medical condition: Chronic Lymphocytic Leukemia
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004864 10009310 CLL LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Trial now transitioned) BE (Trial now transitioned) DK (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2016-004339-19 Sponsor Protocol Number: UTX-TGR-204 Start Date*: 2017-02-16
    Sponsor Name:TG Therapeutics
    Full Title: A Multi-Center, Open-Label, Compassionate Use Extension Study of Ublituximab (TG-1101) in Combination with Umbralisib (TGR-1202) for Patients Previously Enrolled in Protocol UTX-TGR-304
    Medical condition: Chronic Lymphocytic Leukemia
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004864 10008976 Chronic lymphocytic leukemia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: PL (Prematurely Ended) ES (Ongoing) GB (GB - no longer in EU/EEA) IT (Prematurely Ended)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    « Previous 1  2  3  4  5  6  7  8  9  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Fri Jun 13 00:27:30 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA